FDA Approves Monjuvi for Relapsed or Refractory Follicular Lymphoma

The FDA approved Monjuvi with lenalidomide and rituximab for adults with relapsed or refractory follicular ...

JUNE 20, 2025

FDA Grants Accelerated Approval to Epkinly for Relapsed or Refractory Follicular Lymphoma

The FDA has granted accelerated approval to Epkinly, a bispecific CD20-directed CD3 T-cell engager, for adult ...

JUNE 27, 2024

FDA Grants Accelerated Approval to Breyanzi for Follicular Lymphoma

The FDA has granted accelerated approval to Breyanzi for adults with relapsed or refractory follicular lymphoma who ...

MAY 17, 2024

FDA Grants Accelerated Approval to Brukinsa for Relapsed or Refractory Follicular Lymphoma

The FDA granted accelerated approval to Brukinsa with Gazyva for relapsed or refractory follicular lymphoma after ...

MARCH 9, 2024

FDA Grants Accelerated Approval to Ukoniq for Previously Treated MZL and FL

The FDA approved umbralisib (Ukoniq, TG Therapeutics) for adults with relapsed or refractory marginal zone lymphoma ...

FEBRUARY 18, 2021

Revlimid-Rituximab Combo Approved for FL and MZL

The FDA approved lenalidomide (Revlimid, Celgene) in combination with a rituximab product for previously treated ...

JUNE 4, 2019

FDA Approves Gazyva for Previously Untreated Advanced FL

The FDA granted regular approval to obinutuzumab (Gazyva, Genentech) for use in treatment-naive adults with stage ...

NOVEMBER 21, 2017

Rituxan Hycela Approved for FL, DLBCL, CLL

Rituximab and hyaluronidase human (Rituxan Hycela,  Genentech) was approved for subcutaneous injection for the ...

JUNE 23, 2017